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There is a growing need to provide treatment for cannabis users, yet engaging and main-
taining this population in treatment is particularly difficult. Although past research has
focused on the importance of therapeutic alliance on drug treatment outcomes, this is
the first study to examine the dimensions of therapeutic alliance for cannabis users com-
pared with users of alcohol or other drugs in a naturalistic setting. The acceptability of
Internet-delivered interventions for drug and alcohol treatments is also investigated. Par-
ticipants (n= 77) included clients who were receiving outpatient drug and alcohol treatment
at a publicly funded health service, including a Specialist Cannabis Clinic. The results indi-
cated that one particular domain of alliance, Bond, was consistently lower, from both client
and clinician perspectives, for current cannabis users relative to those not currently using
cannabis. Client perceptions of Bond decreased as the severity of cannabis use increased
(r =−0.373, p=0.02). Cannabis Clinic clients did not report a significantly lower Bond
with their clinicians, suggesting that specialized cannabis services may be better placed
to provide appropriate treatment for this population than embedding cannabis treatment
within traditional drug and alcohol treatment teams. In addition, Internet/computer-based
treatments may be one potential way to engage, transition, or retain cannabis users in
treatment.
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INTRODUCTION
Cannabis is the most common illicit substance in the US,Australia,
and in most developed countries, and is increasing in popularity
(1, 2). However, fewer than 10% of cannabis users access treatment
for their cannabis use directly (3).
For people with cannabis use problems (as with users of other
substances), the effects of the drug itself, multiple co-morbidities,
and/or chaotic lifestyles present constant challenges to treatment
engagement, often resulting in short windows of opportunity in
which to provide treatment (4). However, when cannabis users
do attend counseling treatments, including computerized ther-
apy, they report significant improvements in mood and substance
use (5).
There is therefore a need for research to target cannabis users in
treatment, and to better understand and identify potential strate-
gies to maximize engagement. This is particularly important given
the evidence suggesting cannabis users respond better with longer
term treatment (5, 6), and that therapeutic alliance may be an
important factor in maintaining cannabis users in treatment over
the longer term (8, 9).
THERAPEUTIC ALLIANCE
It is generally accepted that forming a strong therapeutic alliance
during counseling will improve treatment outcomes (7, 8). Ther-
apeutic alliance is multidimensional, but generally refers to the
nature of the affective bond and collaborative relationship between
the client and therapist, who are working in cohesion on therapeu-
tic goals and tasks (9, 10). The therapeutic bond is considered a
core component of alliance, and is assessed in most therapeutic
alliance measures. Bond encompasses the emotional connection,
understanding, and support in the client/therapist relationship.
Other dimensions of alliance, such as tasks, goals, and partnership,
are considered more intellectual and outcome-based, focusing
on the client and therapist working jointly toward therapeutic
goals (11, 12).
THE EFFECT OF CANNABIS USE ON ALLIANCE AND TREATMENT
OUTCOMES
Only one previous study has reported on the relationship between
therapeutic alliance and cannabis use. Diamond et al. (13) con-
ducted an investigation using the Cannabis Youth Treatment Study
population (n= 600) to explore the impact of therapeutic alliance
on treatment outcomes and attendance in adolescent cannabis
users. Early alliance, as perceived by the clients, predicted fewer
days of cannabis use at both 3 and 6 months follow-ups.
A range of factors is suggested to have an impact on the estab-
lishment of therapeutic alliance, regardless of the clinical group
under consideration. These include mental health severity (in
particular symptoms of depression and anxiety), age, and gen-
der (14) and should be considered in any examination of alliance
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in treatment. However, other factors, unique to substance using
populations and cannabis users in particular, may pose further
threats to the establishment of therapeutic alliance in this group.
For example, the intoxication and long-term physiological effects
of cannabis may in part explain why this group may be challeng-
ing to engage and retain in traditional substance abuse counseling
treatment. Euphoria, relaxation, time distortion, perceptual alter-
ations, intensified sensory experience, loss of sense of personal
identity, difficulties with the formation and retrieval of memo-
ries and attention difficulties are associated with the short-term
effects of cannabis use (15, 16). Cannabis use also has psycholog-
ical impacts on anxiety, panic, depression, and psychosis, which
can be associated with chronic consumption (17). In addition,
research findings by Kay-Lambkin et al. (18) suggested that people
who used cannabis presented to a treatment trial with signifi-
cantly lower levels of functioning [F(1, 223)= 6.009, p= 0.015],
and significantly higher levels of interpersonal sensitivity [F(1,
216)= 4.674, p= 0.032], than did users of other drugs. Interper-
sonal sensitivity was indicative of recent distress due to feelings
of self-consciousness and inferiority, having feelings easily hurt,
and others being unfriendly or disapproving. Cannabis users also
reported significantly higher paranoid ideation than did users of
other drugs [F(1, 218)= 9.042, p= 0.003]. These factors are sug-
gestive of the potential difficulties for cannabis users to engage
in therapy and could potentially result in them feeling discon-
nected from the treatment process and their therapist, impact-
ing on alliance. The may be particularly true for the emotional
aspects of therapeutic alliance, namely the core component of
therapeutic bond.
THE INTEGRATION OF INTERNET-DELIVERED TREATMENTS FOR DRUG
AND ALCOHOL CLIENTS
Internet-based treatments may be one-way of improving engage-
ment with cannabis users in a treatment for their cannabis use,
given their heightened paranoia, anxiety, and interpersonal sensi-
tivity relative to users of other drugs. Such treatments have been
shown to be effective across a number of therapeutic contexts (19),
and as the demand for Drug and Alcohol Services has remained
strong, the use of Internet-based treatments has grown into the
general substance abuse field (20). After comparing Internet-based
interventions with traditional psychotherapy, and finding simi-
lar results between the two methods, Carroll et al. (21) provide
support for the idea of a computer-assisted therapist model to aug-
ment the treatment provided by clinicians working in services as a
feasible way of improving treatment outcomes. Marsch (22) also
supports this idea, claiming that technology-based interventions
for substance use disorders can function as “clinician-extenders”
to reduce some of the barriers to treatment.
In the first RCT conducted in this area, Kay-Lambkin et al.
(5) investigated the clinical efficacy of the SHADE (Self-Help for
Alcohol and other drug use and Depression) computer treatment
program. It consisted of 10 sessions of combination motiva-
tional interviewing and cognitive behavior therapy delivered via
a computer program, and was compared to a therapist-delivered
equivalent. Results indicated that both computer- and therapist-
delivered treatments yielded similar outcomes in substance use
and depression at 12-month follow-up. Interestingly, SHADE was
most efficacious for people with cannabis use problems and co-
morbid depression when compared to other substances of con-
cern and therapist-delivered treatment, with SHADE cannabis
users reporting twice the reductions in cannabis use as their
therapist-delivered counterparts (5).
THE CURRENT STUDY
This study aims to investigate the association between cannabis
use and therapeutic relationship within a publicly funded Drug
and Alcohol Service, from both client and clinician perspectives,
comparing a general counseling and cannabis-specific services. It
is hypothesized that current users of cannabis will report lower
levels of therapeutic alliance relative to people not currently using
cannabis. It will also examine the acceptability of computers/the
Internet in providing information about and treatment for alco-
hol/other drug use, hypothesizing that cannabis users will be more
open to these modalities than users of other drugs.
MATERIALS AND METHODS
PARTICIPANTS
A total of 77 client participants who were receiving outpatient
drug and alcohol treatment at the Northern Sydney Central Coast
Area Health Service (NSCCAHS, NSW, Australia) were recruited
to this study. Participants were referred from the teams within
the counseling portfolio including; Cannabis Clinic (n= 21),
Drug and Alcohol Counseling (n= 50), and The Magistrates
Early Referral into Treatment program (MERIT) (n= 6). Par-
ticipants were aged between 19 and 69, with a mean age of
40. The majority of participants were Australian born (n= 69,
89.6%), with 2.6% (n= 2) of Aboriginal or Torres Strait Islander
decent. One third of participants were living alone (n= 25),
31% were living with a spouse and/or children (n= 24) and
14% were living with their parents (n= 11). Sixty-four per-
cent were unemployed (n= 49), 55% were males (n= 42) and
46% were single and had never married (n= 35). At baseline
assessment, 51% (n= 39) participants indicated they were seek-
ing treatment primarily for concerns regarding alcohol, 27%
(n= 21) for cannabis, 9% (n= 7) for methamphetamine, 6%
(n= 5) for tobacco, and 3% (n= 2) for heroin and hallucino-
gens (ecstasy) respectively. Abuse/dependence criteria were not
measured as part of the current study, however information pro-
vided by the referring clinicians indicated that the majority of the
sample (n= 56, 72%, those referred via the MERIT and Drug and
Alcohol Counseling programs) met DSM-IV criteria for alcohol
dependence at study entry. Twenty-one participants (27%, those
referred via the Cannabis Clinic) met criteria for cannabis depen-
dence. Participants could have met dependence criteria for several
substances concurrently, however all participants with cannabis
dependence were referred via the Cannabis Clinic. No partici-
pants referred to this service were excluded from participation in
the study.
The clinician participants in this study (n= 16) were employes
of NSCCAHS with tertiary qualifications in psychology (n= 5)
or nursing (n= 11) and were registered in their fields with the
relevant professional organization. Participants in the clinician
group reported a mean age of 42.90 years (SD= 11.17, Range
25–58) and were, for the most part, female (n= 11/16). They all
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provided assessment and treatment according to evidence-based
psychosocial guidelines (23).
MEASURES
A range of demographic and treatment variables were assessed
at the baseline interview. These included age, gender and marital
status as per Kay-Lambkin et al. (24).
The Opiate Treatment Index [OTI; (25)] was used to assess
the quantity and frequency of alcohol/other drug use across
11 individual substances (alcohol, cannabis, heroin, other opi-
ates, methamphetamine, cocaine, tranquilizers, barbiturates, hal-
lucinogens, inhalants, tobacco). For each substance, clients were
asked to report on their last three use occasions in the month prior
to assessment, estimating the amount of each drug consumed on
each of these occasions. An average use index for the previous
month was calculated (OTI q score) as an estimate of quantity
and frequency of use, with a score of 1 indicating once daily use, 2
twice daily use, and so on. Participants received an OTI q score for
each substance. Cannabis use (OTI q score – Cannabis) was used
as a continuous variable in the analysis, and was also categorized
according to the following to facilitate comparisons with users of
other drugs combined (including alcohol):
“Current cannabis use” – this group included people who
reported using any level of cannabis at baseline (n= 37) and
was compared to people not using any cannabis currently (but
were using other drugs including alcohol), as measured by the
OTI q score (n= 40). A proportion of “current cannabis use”
participants (n= 21, referred via the Cannabis Clinic) met cri-
teria for cannabis dependence, however the remainder (n= 16)
did not. This provided a group reporting a range of severity of
cannabis use to be analyzed. No participants in the comparison
group met criteria for cannabis dependence at study entry. All
participants, regardless of categorization, could have been using
other substances concurrently.
“Cannabis Clinic” – this group included people referred to the
study by the Cannabis Clinic clinicians (n= 21) and was com-
pared to people seeking treatment from the Drug and Alcohol
Counseling and MERIT teams (n= 56). The Cannabis Clinic
comprised clinicians specifically trained in engaging and treating
clients with cannabis use problems, and offers services to people
aged 16 years and over who want to quit or reduce their cannabis
use (23). All Cannabis Clinic clients met criteria DSM-IV criteria
for cannabis dependence (provided by the referring clinician).
The comparison group were using a range of substances, but all
met criteria for alcohol dependence at study entry.
The DASS-21 (Depression, Anxiety, and Stress Scale) was used
to measure depression, anxiety, and stress scores (26). Henry and
Crawford (27) assessed the reliability of the DASS-21. A Cronbach
alpha of 0.93 for the total measure was found, as well as high reli-
ability for the stress and depression scales and adequate for the
anxiety scale (0.93, 0.90, and 0.82 respectively).
The Agnew Relationship Measure (ARM) Client Question-
naire (11) was used to measure therapeutic alliance from both
client and clinician perspectives. The dimensions include Bond
(acceptance, support, and understanding in the relationship),
Partnership (working together of tasks in therapy), Confidence
(respect and optimism for the therapist’s competence), Open-
ness (client’s feeling toward disclosure of personal information
without embarrassment or fear), and Client Initiative (client’s
responsibility for direction in therapy). It consists of 28 items used
to measure the five dimensions of the client-therapist alliance.
Agnew-Davis et al. (11) rated the internal consistency and found
that all dimensions had an alpha value between 0.77 and 0.87,
except for Client Initiative, which was 0.55. The ARM has been
used in prior drug and alcohol research and also has strong con-
vergent validity with the Working Alliance Inventory [WAI; (28)]
another popular method of measuring alliance (12).
The Computer Anxiety Questionnaire which includes a Com-
puter Anxiety rating scale [CARS; (29)] and a Computer Thoughts
Survey [CTS; (29)] were used to measure client’s opinions and
anxiety around using computers. The CARS asks respondents
to indicate on a Likert scale (“very much” to “not at all”) how
anxious each of 20 items would make them feel. The CTS asks
respondents to indicate how often they currently have one of 20
specified thoughts when they use a computer or think about using
a computer (“not at all” to “very much”).
Further questions were also asked to explore clients’ open-
ness to using computer/Internet-delivered treatment for their
primary drug of concern. The questions included; “Have you ever
used any computer or Internet-delivered treatment for your men-
tal health or drug and alcohol use issues?” and “If you were offered
computer/Internet-delivered treatment, would you utilize it as part
of your treatment for drug and alcohol and/or mental health prob-
lems?” Using a 4-point Likert scale from “not at all” through to
“a lot” clients were also asked to rate how much they agreed with
the following statements; “Computer/Internet-delivered treatment
could be useful in helping me deal with my alcohol and other drug
use” and “Computer/Internet-delivered treatment could be useful in
helping me find information about alcohol/other drug use.” The Lik-
ert scale questions were then re-coded into two categories (not at
all and not much= no, a little and a lot= yes) due to sample size
and for ease of analysis.
RESEARCH DESIGN
The detailed methods and study design have been out-
lined elsewhere (24). The study received ethics approval from
the relevant organizations (e.g., Northern Sydney Central
Coast Human Research Ethics Committee Approval Number:
08/HARBR/78/79).
Participating clinicians from the Cannabis Clinic and MERIT
teams were asked to introduce the research project and gain con-
sent to release their client’s contact details to the research team
during the initial assessment. It was necessary to ensure that the
clients’decision to participate in the research was entirely indepen-
dent of their treatment with the service, and that if they did not
choose to participant their treatment would not be impacted on in
anyway. There was a longer waitlist for clients seeking treatment
from the Counseling Team therefore consent to release contact
details was done while clients were on the waitlist in order to
engage them with the research earlier in their treatment episode.
Clients were contacted via phone by the research assistant and
invited to participate in the study. At this stage clients were asked if
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they agreed to be contacted in 1 week, during which they received
and considered the information sheet and consent form for the
study. Following the provision of informed consent, assessment
measures were collected over the phone, Clients were offered a $20
reimbursement for their time for completing the phone assess-
ments. Clinicians were unaware if the clients they had referred had
consented to the research, unless told so by the client in therapy.
Clinicians completed therapeutic alliance measure for all clients
after the initial session for the duration of the study.
RESULTS
RECRUITMENT
Recruitment for this study was from August 2010 through to April
2011. During this time 166 clients were referred, of which 56
refused participate, 24 were unable to be contacted and 9 did not
return their consent documents.
STATISTICS AND DATA ANALYSIS
Chi-square analysis was used to examine the interaction between
the two variables “Current cannabis use” (yes/no) and “Cannabis
Clinic” (yes/no; X 21 = 28.14, p= 0.00, n= 77). All participants
referred from the cannabis clinic (n= 21, 27% of total) reported
cannabis use at baseline. Of the remainder (those referred from
the Counseling/MERIT teams), 18 (23% of total) reported current
cannabis use, and 38 (49%) reported no current cannabis use.
No participant referred from the Cannabis Clinic reported zero
cannabis use at baseline. Given the significant overlap between
the “Current cannabis use” and “Cannabis Clinic” variables, and
the zero value of the cell Cannabis Clinic+ no baseline cannabis
use, separate one-way Analysis of Variance (ANOVA) are reported
for examining relationships between each of the cannabis vari-
ables (Current cannabis use and Cannabis Clinic) and the outcome
of interest (e.g., therapeutic alliance, depression, anxiety, stress),
rather than conducting a two-way ANOVA.
At baseline, participants reported use of a range of substances
in the month prior to assessment, including alcohol (Mean= 3.74,
SD 5.62 standard drinks per day), heroin (Mean= 0.10, SD 0.31
use occasions per day), cannabis (Mean= 3.86, SD 8.18 use occa-
sions per day), other opiates (Mean= 0.22, SD 0.62 use occasions
per day), methamphetamine (Mean= 0.16, SD 0.45 use occa-
sions per day), cocaine (Mean= 0.19, SD 0.61 use occasions per
day), tranquilizers (Mean= 0.23, SD 0.62 use occasions per day),
barbiturates (Mean= 0.16, SD 0.49 use occasions per day), hallu-
cinogens (Mean= 0.16, SD 0.49 use occasions per day), inhalants
(Mean= 0.21, SD 0.62 use occasions per day), and tobacco
(Mean= 12.28, SD 12.64 cigarets per day). This was based on par-
ticipant self-report using the OTI, with a score of 0.14 equating to
once weekly use for the prior month, a score of 1 indicating once
daily use for the prior month, and so on. Polydrug use was com-
mon, with participants reporting an average use of 2–3 drug types
in the month prior to baseline (including tobacco; Mean= 2.60,
SD 1.55). One-way ANOVAs indicated no significant differences
in the use of any drug type (with the exception of cannabis) at
baseline for Current versus Non-current cannabis users and par-
ticipants referred from the Cannabis Clinic versus those who were
not. As expected, significantly higher cannabis use was reported
by participants referred from the Cannabis Clinic (Mean= 9.39,
SD12.17 use occasions per day) versus those referred from the
other treatment teams (Mean= 1.50, SD 3.97 use occasions per
day; F(1, 56= 13.654, p= 0.001). The same was true for Current
versus non-current cannabis users.
The impact of demographic variables on client perceptions of
therapeutic alliance
A one-way ANOVA revealed that there were no significant differ-
ences between age and gender on the therapeutic alliance subscales.
The youngest age group (19–30) did score lower, on average, on
all five dimensions of the therapeutic alliance than the other age
groups, however this was not statistically significant. Overall, there
was a trend on the openness dimension of alliance related to age
[F(3, 63)= 2.34, p= 0.082], with Bonferroni post hoc analysis
indicating that 19–30 year olds scored lower than the other age
groups. For gender, males on average scored lower across all of
the therapeutic alliance dimensions than females, although these
differences were not significant.
The impact of cannabis use on client perceptions of therapeutic
alliance
Correlational analysis using cannabis as a continuous variable
(OTI q score) was conducted, and revealed a significant negative
correlation between the amount of cannabis used and Bond on the
client ARM (r =−0.373, p= 0.02, see Table 1). There were no sig-
nificant correlations found between amount of cannabis use and
any other dimension of the client therapeutic alliance measure.
One-way ANOVAs compared past-month cannabis users with
those who did not use cannabis in the past month on the dimen-
sions of the client ARM. There was a significant difference found
between people using cannabis in the past month and people who
did not on the Bond dimension of the ARM, F(1, 65)= 4.923,
p= 0.03. This result, shown in Table 2, suggests that clients who
use any level of cannabis found it significantly more difficult to
develop a therapeutic bond with their clinician at the beginning
of treatment than those who did not use cannabis.
The“Cannabis Clinic”group were compared to people engaged
with either the counseling or MERIT teams on the client ARM
(see Table 3). There were no significant differences between these
groups on the measures.
The impact of mental health symptoms on therapeutic alliance
There were no significant correlations found between depression,
anxiety, and stress (DASS-21) scores and cannabis use in the
month prior to survey (OTI q scores, see Table 1). In addition,
no significant correlations were found between DASS-21 scores
and subscales of the ARM.
A one-way ANOVA also indicated no significant difference
between current cannabis users and non-cannabis-users on the
DASS-21 subscales. However, the mean scores for depression, anx-
iety, and stress were lower for the“current cannabis”and“Cannabis
Clinic” groups, relative to their counterparts (see Tables 4 and 5,
respectively).
The prediction of client perceptions of therapeutic alliance
Given the associations between cannabis use and the ARM subscale
of Bond, a linear regression model was also used to determine the
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Table 1 | Pearson correlation analysis for depression, anxiety, stress
scores (DASS-21), subscales of the Agnew-Davies Relationship
Measure (ARM) of therapeutic alliance (client-rated) and past-month
cannabis use (OTI q Score).
DASS-21
depression
DASS-21
anxiety
DASS-21
stress
Past-month
cannabis use#
ARM-bond −0.020 −0.006 0.040 −0.373*
ARM-partnership 0.084 0.118 0.057 −0.196
ARM-confidence −0.062 −0.114 −0.096 −0.123
ARM-openness 0.103 0.031 0.100 −0.032
ARM-initiative −0.078 0.069 −0.028 −0.149
DASS-21 depression ### 0.748* 0.883* −0.063
DASS-21 anxiety ### ### 0.730* −0.059
DASS-21 stress ### ### ### −0.078
*p< 0.05 #OTI q score.
Table 2 | Current cannabis# users compared to no current cannabis
users on client-rated subscales of the Agnew-Davies Relationship
Measure of therapeutic alliance.
Therapeutic alliance subscales N* Mean SD ANOVA
Bond
Current cannabis use 33 5.91 0.821 F (1, 65)=4.923,
p=0.03No current cannabis use 34 6.31 0.674
Partnership
Current cannabis use 33 5.97 0.848 F (1, 64)=0.511,
p=0.477No current cannabis use 33 6.13 0.929
Confidence
Current cannabis use 33 5.81 0.842 F (1, 65)=0.853,
p=0.359No current cannabis use 34 6.19 2.17
Openness
Current cannabis use 33 5.21 0.996 F (1, 65)=0.040,
p=0.843No current cannabis use 34 5.16 1.18
Initiative
Current cannabis use 33 3.38 0.974 F (1, 65)=0.095,
p=0.759No current cannabis use 34 3.46 1.05
#Current cannabis use refers to people who nominated they had used cannabis (at
any level) in the month prior to assessment. “No current cannabis use” includes
people using a range of substance, but no cannabis, in the month prior to assess-
ment.
*Note some missing data due to incomplete ARM at baseline.
independent contribution of cannabis use to this ARM subscale.
Predictor variables were included in the model if their univari-
ate significance was <0.1. Based on this criterion, age, gender,
and OTI cannabis q scores were included in the regression model.
The regression equation was statistically significant in predicting
Bond [F(3, 63)= 3.800, p= 0.014, r2adj = 0.113], with cannabis
use being the sole significant predictor (p= 0.008).
The impact of cannabis use on clinician perceptions of therapeutic
alliance
One-way ANOVAs were also used to compare the clinician ratings
of the therapeutic alliance dimensions of the ARM for cannabis
Table 3 | “Cannabis Clinic” group compared to other teams
(Counseling and MERIT)# on the client-rated subscales of the
Agnew-Davies Relationship Measure of therapeutic alliance.
Therapeutic alliance subscales N Mean SD ANOVA
Bond
Cannabis clinic 19 5.92 0.73 F (1, 65)=1.664,
p=0.202Counseling/MERIT 48 6.10 0.78
Partnership
Cannabis clinic 19 5.96 0.94 F (1, 64)0.272= ,
p=0.604Counseling/MERIT 47 6.09 0.87
Confidence
Cannabis clinic 19 6.53 2.79 F (1, 65)=2.758,
p=0.102Counseling/MERIT 48 5.79 0.84
Openness
Cannabis clinic 19 5.51 1.08 F (1, 65)=2.474,
p=0.121Counseling/MERIT 48 5.06 1.07
Initiative
Cannabis clinic 19 3.28 1.17 F (1, 65)=0.555,
p=0.459Counseling/MERIT 48 3.48 0.91
#Cannabis Clinic participants all met criteria for cannabis dependence at study
entry, and were referred via a treatment team specifically trained to engage and
treat clients with cannabis use problems. Participants from Counseling/MERIT
teams did met criteria for alcohol dependence, but not cannabis dependence, at
study entry. Participants in each group could have met dependence criteria for
other substances concurrently.
Table 4 | Current cannabis* users versus non-current users as a
function of current depression, anxiety, and stress, as measured by
the DASS-21.
DASS-21 subscales N Mean SD ANOVA
Depression
Current cannabis use 37 16.81 11.99 F (1, 75)=0.194,
p=0.661No current cannabis use 40 18.10 13.57
Anxiety
Current cannabis use 37 9.84 10.77 F (1, 75)=0.355,
p=0.553No current cannabis use 40 11.25 10.02
Stress
Current cannabis use 37 19.96 10.52 F (1, 75)=0.869,
p=0.354No current cannabis use 40 22.35 11.84
*Current cannabis use refers to people who nominated they had used cannabis
(at any level) in the month prior to assessment. “No current cannabis use”
includes people using a range of substance, but no cannabis, in the month prior
to assessment.
users. As shown in Table 6, there was a significant difference found
between current and non-current cannabis users on the Bond
subscale of therapeutic alliance [F(1, 64)= 4.257, p= 0.043], indi-
cating that clinicians seeing clients who were current cannabis
users reported a lower therapeutic bond early in therapy than
non-current cannabis users.
There was also a significant difference found for clinician-
rated Bond for the “Cannabis Clinic” participants when com-
pared to those from other teams [F(1, 64)= 5.560, p= 0.02].
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Table 5 | A comparison of Cannabis Clinic versus MERIT/Counseling
Team# participants on measures of depression, anxiety, and stress
(DASS-21).
DASS-21 subscales N Mean SD ANOVA
Depression
Cannabis clinic 21 15.24 9.02 F (1, 75)=0.890,
p=0.349Counseling/MERIT 56 18.32 13.89
Anxiety
Cannabis clinic 21 8.10 7.76 F (1, 75)=1.669,
p=0.200Counseling/MERIT 56 11.50 11.08
Stress
Cannabis clinic 21 18.51 9.50 F (1, 75)=1.685,
p=0.198Counseling/MERIT 56 22.21 11.72
#Cannabis Clinic participants all met criteria for cannabis dependence at study
entry, and were referred via a treatment team specifically trained to engage and
treat clients with cannabis use problems. Participants from Counseling/MERIT
teams did met criteria for alcohol dependence, but not cannabis dependence, at
study entry. Participants in each group could have met dependence criteria for
other substances concurrently.
Table 6 | Clinician-rated therapeutic alliance (as measured by the
Agnew-Davies Relationship Measure) for current versus non-current
cannabis users*.
Therapeutic alliance subscales N# Mean SD ANOVA
Bond
Current cannabis use 32 5.75 1.01 F (1, 64)=4.257,
p=0.043No current cannabis use 34 6.19 0.70
Partnership
Current cannabis use 32 6.20 4.50 F (1, 64)=0.098,
p=0.756No current cannabis use 34 6.53 4.12
Confidence
Current cannabis use 32 5.26 0.99 F (1, 64)=0.740,
p=0.393No current cannabis use 34 5.45 0.80
Openness
Current cannabis use 32 5.28 4.53 F (1, 64)=0.260,
p=0.612No current cannabis use 34 4.87 1.06
Initiative
Current cannabis use 32 4.40 1.09 F (1, 64)=0.046,
p=0.831No current cannabis use 34 4.34 1.09
*Current cannabis use refers to people who nominated they had used cannabis (at
any level) in the month prior to assessment. “No current cannabis use” includes
people using a range of substance, but no cannabis, in the month prior to assess-
ment.
#Note some missing data due to incomplete ARM at baseline.
This suggested that Cannabis Clinic clinicians reported lower
therapeutic bond with their clients early in therapy, see Table 7.
No significant differences were found for any other subscale of
the clinician-rated therapeutic alliance between Cannabis Clinic
participants and their Counseling/MERIT counterparts. How-
ever, a non-significant trend emerged for clinicians who see
clients at the Cannabis Clinic to report lower confidence in
Table 7 | “Cannabis Clinic” group compared to other teams
(Counseling and MERIT)# on the clinician-rated subscales of the
Agnew-Davies Relationship Measure of therapeutic alliance.
Therapeutic alliance subscales N* Mean SD ANOVA
Bond
Cannabis clinic 18 5.57 0.98 F (1, 64)=5.560,
p=0.021Counseling/MERIT 48 6.13 0.80
Partnership
Cannabis clinic 18 5.22 1.18 F (1, 64) 1.790= ,
p=0.186Counseling/MERIT 47 6.80 4.91
Confidence
Cannabis clinic 18 5.05 1.03 F (1, 64)=2.955,
p=0.090Counseling/MERIT 48 5.47 0.82
Openness
Cannabis clinic 18 5.82 5.88 F (1, 64)=1.340,
p=0.251Counseling/MERIT 48 4.79 1.27
Initiative
Cannabis clinic 18 4.11 0.88 F (1, 64)=1.439,
p=0.235Counseling/MERIT 48 4.46 1.14
#Cannabis Clinic participants all met criteria for cannabis dependence at study
entry, and were referred via a treatment team specifically trained to engage and
treat clients with cannabis use problems. Participants from Counseling/MERIT
teams did met criteria for alcohol dependence, but not cannabis dependence, at
study entry. Participants in each group could have met dependence criteria for
other substances concurrently.
*Note some missing data due to incomplete ARM at baseline.
therapy at baseline compared to clinicians from other teams [F(1,
64)= 2.955, p= 0.090], see Table 7.
Openness to receiving computer-based treatments
Results on the CARS, the CTS, and questions exploring partic-
ipants’ openness to using a computer-delivered treatment were
compared between cannabis and non-cannabis groups using a
one-way ANOVA (see Table 8). There were no significant differ-
ences found between the cannabis and non-cannabis groups on
the CARS and CTS. There was a tendency for the cannabis users
to report lower average scores on the CARS than people using
other drugs, particularly for referrals from the Cannabis Clinic
(M = 28.29) compared to other teams (M = 31.70). This indicates
that cannabis users were somewhat less anxious about the idea of
using a computer, albeit that this was not a statistically significant
difference. Conversely, current cannabis users and Cannabis Clinic
participants reported fewer positive thoughts about computers,
although again, this was not statistically significant.
A continuity-corrected chi squared analysis was used to explore
differences between participants on their openness to using an
Internet-delivered treatment for their primary substance of con-
cern. Although there were no significant differences observed, a
higher proportion of current cannabis users reported previous
use of Internet-delivered treatments compared to non-current
cannabis users [53 versus 35%; χ2(1)= 0.634, p= 0.426]. Simi-
larly, 62% of people from the “Cannabis Clinic” group reported
prior use of Internet-delivered treatments compared to 32% from
other teams [χ2(1)= 1.97, p= 0.161]. There was a tendency
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Table 8 | Responses to the Computer Anxiety Rating Scale (CARS) and the ComputerThoughts Survey (CTS) as a function of
current/non-current cannabis* use and Cannabis Clinic versus Counseling/MERIT participants#.
CARS CTS
Mean (SD) Positive thoughts Mean (SD) Negative thoughts Mean (SD)
Current cannabis use 29.03 (14.01) 22.43 (9.02) 17.59 (9.13)
No current cannabis use 31.70 (12.56) 24.86 (9.03) 19.62 (7.47)
ANOVA F (1, 75)=0.78, p=0.38 F (1, 72)=1.35, p=0.25 F (1, 72)=1.09, p=0.30
Cannabis clinic 28.29, (11.63) 22.81, (8.86) 19.48, (10.88)
Counseling/MERIT 31.21, (13.83) 23.98, (9.18) 18.26, (7.20)
ANOVA F (1, 75)=0.74, p=0.40 F (1, 72)=0.25, p=0.62 F (1, 72)=0.31, p=0.58
*Current cannabis use refers to people who nominated they had used cannabis (at any level) in the month prior to assessment. “No current cannabis use” includes
people using a range of substance, but no cannabis, in the month prior to assessment.
#Cannabis Clinic participants all met criteria for cannabis dependence at study entry, and were referred via a treatment team specifically trained to engage and treat
clients with cannabis use problems. Participants from Counseling/MERIT teams did met criteria for alcohol dependence, but not cannabis dependence, at study entry.
Participants in each group could have met dependence criteria for other substances concurrently.
for cannabis users to think that Internet-delivered treatments
could be useful in locating information about or treatment for
their primary drug of concern. For example, 87% of current
cannabis users people agreed that the Internet would useful
in helping them deal with their primary drug, compared to
70% of people with no current cannabis use [χ2(1)= 0.675,
p= 0.411]. Ninety-two percent of Cannabis Clinic participants
indicated they would utilize Internet-delivered treatment if offered
to them, compared with 75% of people referred from other teams
[χ2(1)= 0.712, p= 0.389].
DISCUSSION
This is the first study to explore differences in therapeutic alliance
for cannabis users compared with users of alcohol or other drugs
in a naturalistic setting. The results indicate that one particular
domain of alliance, Bond, is consistently different, from both client
and clinician perspectives, for current cannabis users relative to
people not currently using cannabis. There was evidence for the
client’s perception of Bond to decrease as the severity of cannabis
use increased. Cannabis use remained a significant independent
predictor of client-related Bond when age and gender were taken
into account via the regression analysis. This was also the case
for clinicians’ perceptions of Bond. The results are elaborated on
below.
THE BOND DIMENSION OF THERAPEUTIC ALLIANCE
The Bond dimension is different from the other therapeutic
alliance dimensions. Questions on the Bond dimension of the
client ARM include; “I feel friendly toward my therapist,” “I feel
accepted in therapy no matter what I say or do,” “I find therapy
warm and friendly,” and “My therapist is supportive.” These state-
ments incorporate emotional language and ask the client to report
on their feelings toward the therapist on an individual level. The
other core dimensions of alliance measured by the ARM, part-
nership and confidence, focus more on practical issues and ask
the client to comment on the working relationship such as “My
therapist and I agree how to work together,” “My therapist and I
are willing to work hard together,” “I have confidence in the therapy
and the techniques being used,” and “The professional skills of the
therapist are impressive” (11).
The impact of cannabis on clients’ perceptions of Bond
Client perspectives of therapeutic bond were significantly lower
for current cannabis users than non-current users however this
difference was not seen for the “Cannabis Clinic” groups. Given
that the Bond dimension incorporates the emotional attach-
ment between the client and clinician, one possible explanation
is that the effects of current cannabis use might impact on a
person’s ability to form this emotional connection. Perhaps a
combination of the lower interpersonal sensitivity, heightened
paranoia, loss of personal identity, and anxiety that have been
associated with chronic cannabis use (15, 16, 18) result in the
client feeling emotionally numbed or disconnected from the clin-
ician during treatment. Anecdotally, current cannabis users often
describe a pattern of smoking cannabis throughout the night
and first thing when they wake of a morning. It may be that
current cannabis users are likely to attend treatment whilst intox-
icated by the effects of their drug then people who are seeking
treatment for methamphetamine or alcohol who may have a
different pattern of use. This may explain the reported differ-
ences and difficulties in establishing a therapeutic bond with their
therapist.
EXPLORING THE IMPACT OF A SPECIALIZED CANNABIS SERVICE ON
PERCEPTIONS OF ALLIANCE
Interestingly, people referred to the study from the Specialist
Cannabis Clinic did not report a lower perception of therapeu-
tic bond than clients seeking treatment from other teams. Per-
haps this might be explained by treatment motivation. Cannabis
Clinic clients typically want to engage in treatment for the pur-
pose of reducing or ceasing their cannabis use. Perhaps, in this
context, the partnership with the therapist around tasks and
goals is established more easily, allowing the clinician more
time to focus on their emotional connection with the client.
This is perhaps one demonstration of the benefits and impor-
tance of a specialized cannabis treatment team, physically located
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separately from people seeking treatment for other drugs, and
staffed by specialist clinicians with additional training and sup-
port in how to engage and manage people with current cannabis
use problems.
Therapist-related factors may also have impacted on this result,
as different clinicians were operating across the three clinical set-
tings targeted in the current study. Given the development of
therapeutic bond is one involving personal factors, and that the
therapist too, brings their own qualities to the therapeutic rela-
tionship, it is also possible that these qualities differed across
the clinics and thus contributed to the differences in results
between clinics. A testament to this was the significantly lower
ratings of the clinicians’ perspective of Bond, which was signif-
icantly lower for Cannabis Clinic clients than for clients from
other teams. There was also a trend for clinicians from the
Cannabis Clinic to report lower scores on the Confidence dimen-
sion then clinicians from other teams, suggesting that Cannabis
Clinic clinicians have less confidence and optimism in ther-
apy and their techniques. When considering these results it is
important to note that there were a small number of people
using cannabis in the other teams and individual clinician dif-
ferences may have influenced these outcomes. However, these
results may also indicate that clinicians working within the Spe-
cialized Cannabis Clinic are more aware of the difficulties of
engaging cannabis users and in some way account or compen-
sate for the lack of emotional connection with their clients.
These findings provide useful information for individuals provid-
ing supervision or training for therapists working with cannabis
clients.
THE IMPACT OF AGE, GENDER, ANDMENTAL HEALTH ON THERAPEUTIC
ALLIANCE
In general, there was a tendency for the youngest age group to score
lower on the client therapeutic alliance subscales, particularly for
Openness. Males also scored consistently lower on the therapeutic
alliance measure than females. There were no significant differ-
ences found between age and gender on the therapeutic alliance
dimensions, in contrast to previous research (14). Perhaps in the
current study, the effects of drug use over-ride any potential age
and gender differences in the establishment of therapeutic alliance;
an issue that warrants further investigation.
There were no significant correlations found between depres-
sion, anxiety, and stress (DASS-21) scores, the dimensions on the
client therapeutic alliance measure and amount of cannabis use.
This finding is similar to Diamond et al. (13) who found no sig-
nificant impact of mental health symptoms on early therapeutic
alliance in their study with young cannabis users. There were also
no significant differences found between current and non-current
cannabis users on the DASS-21 scores. This may have been due
to a ceiling effect, whereby our study participants scored much
higher than population norms on the depression, anxiety, and
stress subscales. If the notion of the intoxication and chronic
effects of cannabis use resulting in a person becoming emotion-
ally disconnected is correct, then perhaps cannabis might impact
on a person’s own level of insight into their emotional health,
given the negative correlation between amount of cannabis use
and perceived Bond with their clinician.
EXPLORING THE USE OF COMPUTER-BASED INTERVENTIONS FOR
CANNABIS USERS
In general, our hypotheses related to differences between cannabis
users and users of other drugs in terms of openness to
computer/Internet-delivered treatment modalities were not sup-
ported. However, current cannabis users tended to be less anxious
than non-current users about the idea of using computers, scor-
ing lower on the CARS. Conversely, the current cannabis group
reported fewer positive thoughts about computers than did their
counterparts on the CTS. Both of these results were not significant.
This finding potentially also supports the above notion of cannabis
users being emotionally disconnected from their experiences in
general, rather than specifically about the use of computers/the
Internet. In this context, however, the potential advantage of
this finding is that cannabis users may be willing to at least try
alternative modes of delivery of treatment.
A higher proportion of people from the current cannabis use
groups reported previous exposure to Internet-delivered treat-
ments; thought that Internet-delivered treatments could be useful
managing their primary drug of concern; and were more willing to
use Internet-delivered treatment when compared to non-current
cannabis users. Although not significant, these results generally
highlight the potential of the Internet in supporting treatments
for cannabis users. This particular modality of treatment is of rel-
evance because the Internet can increase the reach of therapy out-
side an individual treatment session, and can overcome logistical
and emotional barriers to attending regular treatment appoint-
ments with a therapist. Such barriers might include basic issues of
organization and functioning, such as getting to the treatment ses-
sion in a clinic, through to reducing any anxiety or reluctance that
might be associated with interacting with a clinician in a treat-
ment program. Internet-delivered treatment could also be used
as a transition into therapy for current cannabis using clients by
introducing psychological concepts and building insight. Future
research could consider these issues specifically for cannabis users
relative to those using other drugs.
Previous research has indicated there is no negative impact
of computer-based treatments on the therapeutic alliance when
integrated with existing psychosocial treatments (30), so given
cannabis users reported particular difficulty building a therapeutic
bond with their therapist, have heightened paranoia and interper-
sonal sensitivity, Internet-based treatments may be one potential
way to engage, transition, or retain this growing population in
treatment.
LIMITATIONS
A limitation of this study was the referral of client participants
by clinicians. Due to client confidentiality within the service this
method appeared the most ethical option however it did leave the
door open for clinician bias. Clinicians may have unintentionally
put their own bias on their referrals potentially referring a certain
type of client and not referring others. In addition, even though
clinicians did not know which of their clients had actually con-
sented to participate in the study they were aware of who had
been referred, potentially impacting on their ratings of therapeu-
tic alliance. It may also be difficult to generalize these findings
beyond an outpatient treatment setting, as cannabis users who do
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not access treatment may be different from those who do. How-
ever, it is likely that similar issues with emotional numbing and
interpersonal difficulties would be evident in non-treatment seek-
ing cannabis users, and may in fact be pivotal in their decisions
not to seek treatment. Future research with general community
samples might be important to pursue.
CONCLUSION
Cannabis users can be reluctant to seek treatment and there are
often high treatment “drop-out” rates associated with counseling
interventions, which have proven effectiveness, and are often pre-
ferred (20). Given that service factors have the ability to influence
engagement with clients in drug treatment (31) and from the evi-
dence found in this study, it is clear that research needs to focus on
the engagement and retention of this particularly difficult client
group from a service perspective, and how to better support and
train clinicians working with cannabis users. Our results suggest
that a focus on developing and improving the therapeutic bond
between client and therapist is an important starting point in this
process. The implementation of Internet/computer-based inter-
ventions for the treatment of cannabis use and associated problems
may take us one step closer to improving treatment outcomes. To
date, no research has investigated the effectiveness of computer-
ized treatments, integrated with standard psychosocial treatments,
specifically with cannabis users in a real world setting.
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